Psychedelic medicines such as psilocybin, MDMA, ketamine, and LSD have been shown to have a significant impact on conditions such as major depressive disorder, generalized anxiety disorder, and post-traumatic stress disorder in clinical trials.
The co-founders of PPA discuss the importance of advocacy work at this point in the development of the psychedelic medicine industry to help cement pharmacist’s role in the continuum of care.
“We shouldn’t let the stigma from the 1960s and ’70s and the War on Drugs prevent us from exploring [something] that can truly help people achieve sustained relief.” By Alexander Lekhtman, Filter Pennsylvania state lawmakers are pushing for legislation that supports research on psilocybin mushrooms for mental health treatment. The bill comes amid a wave […]